Prosthetic joint infections (PJIs) caused by Candida species are serious complications following joint replacement surgeries, with a study reviewing 269 cases between 2010 and 2021 to assess treatment outcomes.
The majority of infections occurred in older patients (average age 73), primarily in hips and knees, and most cases involved additional bacterial infections; roughly 58% achieved a cure at the two-year follow-up.
Treatment effectiveness varied significantly depending on the surgical method used, with poorer outcomes linked to the debridement, antibiotics, and implant retention (DAIR) approach and patients older than 70, while infections from Candida parapsilosis tended to have better outcomes.
- Temocillin, used in some European countries for years, was introduced in France in 2015, and a study evaluated its effectiveness against Enterobacterales strains from blood cultures across three years: 2014, 2015, and 2017.
- Among the 1,387 strains analyzed, the overall resistance rate to temocillin increased from 13.9% in 2014 to 23.9% in 2017, with higher resistance in cephalosporinase-overproducer strains compared to ESBL-producer strains.
- Despite the rising trend in resistance, temocillin remains effective against Enterobacterales, suggesting the need for ongoing monitoring of resistance patterns over time.
The study aimed to compare the risk of infective endocarditis (IE) following percutaneous pulmonary valve implantation (PPVI) using two different valves, the Melody and Sapien.
Results showed that out of 79 patients, 10.1% developed IE, all occurring in those who received the Melody valve, indicating a potential higher risk with this valve compared to the Sapien.
The incidence of IE post-Melody PPVI was found to be significant, with cumulative rates of 24.0% after 4 years and 30.1% after 6 years, while no cases were reported with the Sapien valve over the same time frame.